New Brain Models, Sensors, and Imaging Tools Speed Drug Development
New 3D brain tissue models, laser imaging, and organoid sensors aim to speed drug development for Alzheimer’s and other neurological diseases. The LMU model replicates Alzheimer’s aggregates, MIT’s laser images the blood-brain barrier at record speed, and UNC’s sensor records neural activity without damaging organoids.
Three separate research teams have unveiled new technologies that aim to accelerate the study of brain diseases and the development of potential treatments. The advances include a 3D human brain tissue model that replicates Alzheimer’s pathology, a laser-based imaging method that visualizes the blood-brain barrier at unprecedented speed, and a flexible sensor that captures neural activity from miniature brain organoids.
In a study published in Nature Neuroscience, neuroscientists at LMU University Hospital developed a reproducible three-dimensional model of human brain tissue. The system uses human stem cells converted into neurons, astrocytes, and microglial cells, which self-organize into spheroids within a week. The model actively expresses genes and proteins relevant to Alzheimer’s disease, and researchers successfully induced the formation of amyloid aggregates and dissolved them with new drugs. The team says the system could help accelerate drug development and is working on robotic automation to manufacture hundreds or thousands of disease-model tissues for large-scale drug testing.
Separately, MIT researchers report in Nature Methods that chaotic laser light can spontaneously form a highly focused “pencil beam” under specific conditions. The beam enabled 3D imaging of the human blood-brain barrier at speeds about 25 times faster than current gold-standard techniques, while maintaining similar image quality. The method also allows real-time observation of how individual cells absorb drugs. It requires only a perfectly aligned laser entry and high power, without complex optical engineering. The advance could help evaluate whether treatments for conditions like Alzheimer’s or ALS actually reach their targets in the brain.
A team at the University of North Carolina at Chapel Hill has created a 3D sensor that wraps around brain organoids. Unlike flat 2D electrode arrays, the sensor captures neural signals from all directions without damaging the organoid or requiring chemical glue. This allows repeated use and reduces the preparation time from seven days to 10–20 minutes. The researchers, who have filed a patent, envision the sensor as a commercial product for faster drug screening and personalized medicine, with potential integrations for optogenetics and microfluidic drug application.